| SHR-A1921 / Jiangsu Hengrui Pharma |
NCT06394492: SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer |
|
|
| Not yet recruiting | 3 | 440 | RoW | SHR-A1921, Doxorubicin, Paclitaxel, Topotecan | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Ovarian Cancer | 05/26 | 12/26 | | |
NCT06211023: A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer |
|
|
| Not yet recruiting | 2/3 | 520 | NA | SHR-1921, carboplatin, platinum-based doublet chemotherapy | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Ovarian Cancer | 06/26 | 06/26 | | |
NCT06210438: SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases |
|
|
| Not yet recruiting | 2 | 24 | RoW | SHR-A1921 + Bevacizumab | Fudan University | TNBC, Brain Metastasis | 06/25 | 06/26 | | |
NCT06145308: Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing |
|
|
| Recruiting | 2 | 30 | RoW | Vedolizumab, larotinib or enttraitinib, antiandrogen drug treatment, leprerelin + bicalutamide ± Abiraterone 1000mg po qd, ESG401, small molecule multi-target tyrosine kinase inhibitors± Chemioterapy, apatinib or erlotinib, albumin paclitaxel with platinum | Peking Union Medical College, Peking University Hospital of Stomatology | Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma, Neoadjuvant or Conversion Therapy, Precision Therapy | 07/26 | 07/26 | | |
NCT06465238: Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC |
|
|
| Not yet recruiting | 2 | 30 | RoW | SHR-A2009, SHR-A1921 | Henan Cancer Hospital | NSCLC | 06/26 | 06/27 | | |
NCT06433609: Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer |
|
|
| Not yet recruiting | 2 | 131 | RoW | SHR-A1811, SHR-A1921, Adebrelimab | Beijing GoBroad Hospital | Advanced Breast Cancer | 07/27 | 11/27 | | |
NCT06470672: Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer |
|
|
| Not yet recruiting | 2 | 32 | RoW | SHR-A1921, Adebrelimab | Fudan University | Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | 03/26 | 07/26 | | |
NCT06480136: SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Failed the Previous Standard First-line Treatment |
|
|
| Not yet recruiting | 2 | 32 | NA | SHR-A1921 injection and adebrelimab injection | Shanghai Pulmonary Hospital, Shanghai, China | NSCLC | 06/27 | 02/28 | | |
NCT05924256: A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing |
|
|
| Recruiting | 2 | 88 | RoW | SHR-A1811, SHR 3680 + leuprolide, SHR-A1921 | Fudan University | Advanced Salivary Gland Carcinoma | 09/25 | 09/26 | | |
NCT06385678: A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation |
|
|
| Not yet recruiting | 1/2 | 70 | RoW | HRS-4642, Adebrelimab, SHR-A1921, Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection | Jiangsu HengRui Medicine Co., Ltd. | Advanced KRAS G12D Mutant Solid Tumors | 10/25 | 08/26 | | |
SHR-A1921-205, NCT06434103: Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC |
|
|
| Not yet recruiting | 1/2 | 124 | NA | SHR-A1921；Adebrelimab；SHR-8068；carboplatin | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Non-small Cell Lung Cancer | 06/25 | 03/27 | | |
NCT06474455: A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 156 | RoW | SHR-9839 ；SHR-A2009, SHR-9839 ； SHR-A1921, SHR-9839 ； pemetrexed ；carboplatin, SHR-9839 ； Almonertinib | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 06/26 | 06/27 | | |
FASCINATE-N, NCT05582499: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy |
|
|
| Recruiting | 1/2 | 716 | RoW | Dalpiciclib, SHR-6390, Pyrotinib, SHR-A1811, SHR-1316, Camrelizumab, SHR-1210, SHR-A1921, Pertuzumab, Trastuzumab, Goserelin, Letrozole, Nab paclitaxel, Carboplatin, Epirubicin, Cyclophosphamide, Fluzoparib, SHR-3162, Apatinib, Famitinib | Fudan University | Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer | 09/24 | 09/25 | | |
NCT05765032: Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 120 | RoW | SHR-A1921； | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumor | 04/25 | 02/26 | | |
NCT05594875: A Trial of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors |
|
|
| Completed | 1 | 9 | RoW | SHR-1921 | Atridia Pty Ltd. | Advanced Solid Tumor | 04/24 | 04/24 | | |
| Not yet recruiting | 1 | 156 | NA | SHR-A1921 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumours | 08/24 | 08/24 | | |
